[webinar] Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases
Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.
Speakers:
Dr Sylvie Maubant, Head of Study & Research Unit - In Vivo Sciences Department, Oncodesign
Dr Ivan Gladwyn-Ng, Field Application Scientist, Taconic
Abstract:
Even if the causality is not always established, a microbial imbalance or dysbiosis are being increasingly linked to several diseases, including gastrointestinal and dermal diseases, metabolic disorders, CNS pathologies and cancer. Furthermore, the microbiome has been shown to influence the efficacy of immunotherapy and chemotherapeutic agents and the metabolism of drugs. Based on preclinical and clinical studies, different strategies (e.g., fecal material, defined consortium, single strain) are adopted to modulate the composition of the microbiome and exploit its immunogenicity to treat diseases in first line treatment or to circumvent primary resistance to standard of care.
Owing to their scientific and technological expertise, Oncodesign and Taconic propose tailor-made strategies to clients for investigating the safety/efficacy of their microbiome-based therapeutics. This presentation will focus specifically on applications related to the use of pathogen-free and germ-free mice as preclinical models.
More details about SOLO-Microbiome : https://www.oncodesign.com/fr/service...